

***Amendments to the Claims***

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-40. (canceled)

41. (new) A composition comprising the peptides

RLLQETELV (SEQ ID NO:2),  
YLQLVFGIEV (SEQ ID NO:3),  
LLTFWNPPV (SEQ ID NO:4),  
SMPPPGRV (SEQ ID NO:5),  
KLBPVQLWV (SEQ ID NO:6),  
KVFGSLAFV (SEQ ID NO:7), and  
YLSGADLNL (SEQ ID NO:8);

wherein each of said peptides is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog.

42. (new) A composition comprising the peptides

RLLQETELV (SEQ ID NO:2),  
YLQLVFGIEV (SEQ ID NO:3),  
LLTFWNPPV (SEQ ID NO:4),  
SMPPPGRV (SEQ ID NO:5),  
KLBPVQLWV (SEQ ID NO:6),  
KVFGSLAFV (SEQ ID NO:7),  
YLSGADLNL (SEQ ID NO:8), and  
IMIGHLVGV (SEQ ID NO:9);

wherein each of said peptides is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog.

43. (new) A composition comprising the peptides

RLLQETELV (SEQ ID NO:2),  
YLQLVFGIEV (SEQ ID NO:3),  
LLTFWNPPV (SEQ ID NO:4),  
SMPPPGTRV (SEQ ID NO:5),  
KLBPVQLWV (SEQ ID NO:6),  
KVFGSLAFV (SEQ ID NO:7),  
YLSGADLNL (SEQ ID NO:8),  
IMIGHLVGV (SEQ ID NO:9), and  
KVAEIVHFL (SEQ ID NO:10);

wherein each of said peptides is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog.

44. (new) The composition according to claim 41, further comprising an additional peptide, wherein said additional peptide is less than 25 amino acid residues in length and comprises an helper T lymphocyte (HTL) epitope.

45. (new) The composition according to claim 44, wherein said additional peptide is a PanDR binding peptide.

46. (new) The composition according to claim 45, wherein said Pan DR binding peptide comprises the amino acid sequence aKXVAAWTLKAAa (SEQ ID NO:1).

47. (new) The composition according to claim 41, further comprising a liposome.

48. (new) The composition according to claim 41, further comprising a lipid.

49. (new) The composition according to claim 41, further comprising a pharmaceutical excipient.

50. (new) The composition according to claim 49, wherein said pharmaceutical excipient is an adjuvant.

51. (new) The composition according to claim 50, wherein said adjuvant is a mineral oil adjuvant.

52. (new) A method for the treatment or prevention of cancer, said method comprising administering the composition of claim 41 to a patient in need thereof.

53. (new) The method according to claim 52, wherein said cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, non-small cell lung cancer, ovarian cancer, gastric cancer, melanoma and a cancer of the head and/or neck.

54. (new) A composition consisting essentially of the peptides

RLLQETELV (SEQ ID NO:2),  
YLQLVFGIEV (SEQ ID NO:3),  
LLTFWNPPV (SEQ ID NO:4),  
SMPPPGRTRV (SEQ ID NO:5),  
KLBPVQLWV (SEQ ID NO:6),  
KVFGSLAFV (SEQ ID NO:7),  
YLSGADLNL (SEQ ID NO:8),  
IMIGHLVGV (SEQ ID NO:9),  
KVAEIVHFL (SEQ ID NO:10), and  
aKXVAAWTLKAAa (SEQ ID NO:1).

55. (new) The composition according to claim 54, further comprising a liposome.

56. (new) The composition according to claim 54, further comprising a lipid.
57. (new) The composition according to claim 54, further comprising a pharmaceutical excipient.
58. (new) The composition according to claim 57, wherein said pharmaceutical excipient is an adjuvant.
59. (new) The composition according to claim 58, wherein said adjuvant is a mineral oil adjuvant.
60. (new) A method for the treatment or prevention of cancer, said method comprising administering the composition of claim 54 to a patient in need thereof.
61. (new) The method according to claim 60, wherein said cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, non-small cell lung cancer, ovarian cancer, gastric cancer, melanoma and a cancer of the head and/or neck.